Anzeige
Mehr »
Freitag, 09.05.2025 - Börsentäglich über 12.000 News
Rallye naht! Die Wette eines Milliardärs auf die Zukunft des Kupfers...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D4G4 | ISIN: US13471N3008 | Ticker-Symbol: CF5
NASDAQ
08.05.25 | 19:29
1,115 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CAN-FITE BIOPHARMA LTD ADR Chart 1 Jahr
5-Tage-Chart
CAN-FITE BIOPHARMA LTD ADR 5-Tage-Chart

Aktuelle News zur CAN-FITE BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoCan-Fite BioPharma Ltd. - 6-K, Report of foreign issuer1
17.04.Can-Fite BioPharma Ltd.: Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients71Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs...
► Artikel lesen
14.04.Can-Fite BioPharma Ltd.: Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares2
14.04.Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.67M1
14.04.Can-Fite BioPharma Ltd.: Can-Fite Reports 2024 Financial Results and Clinical Update161RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs...
► Artikel lesen
14.04.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer2
CAN-FITE BIOPHARMA Aktie jetzt für 0€ handeln
14.04.Can-Fite BioPharma Ltd. - 20-F, Annual and transition report of foreign private issuers2
28.03.RedChip Companies, Inc.: bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV289ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the...
► Artikel lesen
24.03.Can-Fite BioPharma Ltd.: Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol205The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF)...
► Artikel lesen
20.03.Can-Fite BioPharma Ltd.: Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market142Can-Fite's upfront and royalties on sales upon regulatory approval of Piclidenoson for veterinary use, is projected to be $325 million in the aggregate over the next decade assuming a 2029 launch...
► Artikel lesen
19.03.Can-Fite BioPharma Ltd.: Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson237FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients Ramat Gan, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE...
► Artikel lesen
18.03.Can-Fite BioPharma To Offer Compassionate Use Program With Namodenoson-
18.03.Can-Fite BioPharma Ltd.: Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient2
18.03.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer1
03.03.Can-Fite BioPharma Ltd.: Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits3
03.03.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer-
18.02.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer-
10.02.Can-Fite BioPharma Ltd.: Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 251
05.02.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer-
28.01.Can-Fite BioPharma secures US patent for Namodenoson2
Seite:  Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1